Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEARL5 study of DA-EPOCH-R plus high-dose methotrexate in newly diagnosed CD5-positive DLBCL
jRCTs041180159Phase 2Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Nov 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab, etoposide, prednisone, vincristine, cyclophosphamide and 2 more in diffuse large B-cell lymphoma (DLBCL), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: 2-year progression-free survival rate. Started Nov 2012; status: completed.
02
Drugs
rituximabetoposideprednisonevincristinecyclophosphamide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on jRCTs041180159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041180159.